A Randomized, Open-label, Phase 2 Study to Evaluate Safety and Efficacy of DUR-928 in Subjects With Primary Sclerosing Cholangitis (PSC)
Phase of Trial: Phase II
Latest Information Update: 21 Apr 2018
At a glance
- Drugs DUR 928 (Primary)
- Indications Primary sclerosing cholangitis
- Focus Adverse reactions; Therapeutic Use
- Sponsors DURECT Corporation
- 26 Feb 2018 According to a DURECT Corporation media release, the company has commenced patient dosing in this trial at California Pacific Medical Center. Data anticipated in 2018.
- 20 Feb 2018 According to a DURECT Corporation medis release, review on this trial will be presented in a Webcast on February 26 2018 at 12:00 p.m.
- 08 Jan 2018 Status changed from planning to recruiting.